Transaction · 0000950170-25-032747

Guyer William

Guyer William, CDO, reported an open-market or private sale at CORCEPT THERAPEUTICS INC involving 20000.000000 shares for an estimated $1181400.00. Reported holdings after the transaction were 5487.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCDO
CORTCORCEPT THERAPEUTICS INC
Filing timeMar 05
Trade dateMar 04, 2025
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
—
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

CORT price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
CORT since 2025-03-05Filed 548 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0000950170-25-032747
Common Stock
Transaction date
Mar 04, 2025
Filed Mar 05, 2025, 12:53 AM · 1d delay
Shares
20.0k sh
$5.90k per share
Estimated value
-$118M
Computed from shares × price
Holdings after
5.48k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Cluster Selling Direct Ownership Large Holdings Reduction Large Sale 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Development Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.

  2. F2

    Exercise ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date.

  3. F3

    Fully exercisable.

Original filing · 0000950170-25-032747
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

CORT